You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Claims for Patent: 9,211,316

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,211,316

Title:	Collagenase G and Collagenase H compositions for the treatment of diseases involving alterations of collagen
Abstract:	Compositions comprising collagenase G and collagenase H (in a ratio between 1:2.5 and 1:3.5), optionally formulated in hydrogels, and its uses as medicament for the treatment of diseases involving alterations of collagen, such as fibromatosis, palmar Dupuytren\'s contracture, La Peyronie\'s disease, Ledderhose\'s disease or retractable scars.
Inventor(s):	Munoz Montano; Juan Ramon (Madrid, ES)
Assignee:	PROTEOS BIOTECH S.L.U. (Albacete, ES)
Application Number:	13/876,674
Patent Claims:	1. A composition comprising recombinant Collagenase G and recombinant Collagenase H having a mass ratio between 1:2.5 and 1:3.5, wherein the recombinant Collagenase G has the amino acid sequence of SEQ ID NO: 1 and the recombinant Collagenase H has the amino acid sequence SEQ ID NO: 2. 2. A kit comprising recombinant Collagenase G and recombinant Collagenase H having a mass ratio between 1:2.5 and 1:3.5, wherein the recombinant Collagenase G has the amino acid sequence of SEQ ID NO: 1 and the recombinant Collagenase H has the amino acid sequence SEQ ID NO: 2. 3. The composition according to claim 1, wherein the recombinant Collagenase G and/or recombinant collagenase H have a 6-histidine tag located at the C-terminus of their amino acid sequence. 4. The composition according to claim 1, wherein the composition is a pharmaceutical composition. 5. The composition according to claim 1, which also comprises a pharmaceutically acceptable carrier. 6. The composition according to claim 1, further comprising another active ingredient. 7. A pharmaceutical composition comprising the composition according to claim 1. 8. The pharmaceutical composition according to the claim 7 which is selected from the group consisting of: plasters, ointment, paste, cream, solution, suspension, emulsion, lotion, liniment, jelly, gel, foam, powder, and any combination thereof. 9. The pharmaceutical composition according to claim 7, comprising hyaluronic acid in concentrations of between 0.05% and 4%. 10. The pharmaceutical composition according to claim 9, wherein the hyaluronic acid is in a concentration of about 1.5%. 11. The pharmaceutical composition according to claim 9, wherein the concentrations of collagenases are higher than 400 CDU/mg of hyaluronic acid. 12. The pharmaceutical composition according to claim 9, wherein the concentrations of collagenases ranges between 450 and 5000 CDU/mg of hyaluronic acid. 13. The pharmaceutical composition according to claim 9, wherein the hyaluronic acid has a molecular weight between 500 and 5,000 kDa. 14. The pharmaceutical composition according to claim 9, wherein the hyaluronic acid has a molecular weight of approximately 850 kDa. 15. The composition according to claim 1, for use as a medicament. 16. A method for the treatment of diseases involving alterations in connective tissue or fibromatosis, said method comprising administering to a subject in need thereof a therapeutically effective amount of the kit according to claim 2. 17. A method for the treatment of diseases involving alterations in connective tissue, said method comprising administering to a subject in need thereof a therapeutically effective amount of the composition according to claim 1. 18. A method for the treatment of fibromatosis, said method comprising administering to a subject in need thereof a therapeutically effective amount of the composition according to claim 1. 19. The method according to claim 18, wherein the fibromatosis is selected from the group consisting of: palmar Dupuytren's contracture, La Peyronie's disease, Ledderhose's disease or plantar fascial fibromatosis, and retractable scars. 20. A method for the treatment of diseases involving alterations in connective tissue or fibromatosis, said method comprising administering to a subject in need thereof a therapeutically effective amount a kit according to claim 2, said method comprising administering collagenase G before or simultaneously with collagenase H.

Details for Patent 9,211,316

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965	⤷ Try a Trial	2030-09-30
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.